Lupin today announced its strategic collaboration with LABORATORIOS ERN S.A. (ERN), a well-established Spanish pharmaceutical company, for the launch of Luforbec® (beclometasone/formoterol) 100/6, a fixed dose combination in a pressurized metered dose inhaler, for the treatment of adult asthma and chronic obstructive pulmonary disease, in Spain.

This collaboration combines Lupin's global respiratory expertise and proven pMDI manufacturing excellence and ERN's robust national reach and deep customer relationships, marking an exciting milestone in expanding high-quality respiratory care to patients across Spain.